1936529-65-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(2-chloro-6-methylphenyl)-7-(2-methoxy-4-(1-methylpiperidin-4-yl)phenylamino)-1-(5-methoxypyridin-2-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one is used as a potential pharmaceutical compound for its possible biological activity and pharmacological properties. Its unique structure with various functional groups may contribute to its efficacy in treating specific medical conditions or diseases.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-(2-chloro-6-methylphenyl)-7-(2-methoxy-4-(1-methylpiperidin-4-yl)phenylamino)-1-(5-methoxypyridin-2-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one serves as a subject for further research and characterization. Understanding its properties and interactions with biological targets can lead to the development of new drugs and therapeutic agents.
Note: The specific applications and industries for this chemical are not explicitly provided in the materials. The uses listed above are inferred based on the potential of its structural features and are subject to further research and validation.

Upstream product

• 7627-44-3 2, 4-dichloro-5-(iodomethyl)pyrimidine 
• 7627-38-5 2,4-dichloro-5-(chloromethyl)pyrimidine 
• 4433-40-3 5-hydroxymethyl uracil 
• 1124330-14-8 2-methoxy-4-(1-methylpiperidin-4-yl)aniline 
• 10167-97-2 2-amino-5-methoxypyridine 
• 638352-78-0 1-(5-methoxypyridin-2-yl)-2,5-dimethyl-1H-pyrrole 
• 477889-91-1 1-(5-iodopyridin-2-yl)-2,5-dimethyl-1H-pyrrole 

Relevant academic research and scientific papers

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.